Myeong-Ki Hong

Featured in: Favicon

sciencedirect.com Favicon

jamanetwork.com Favicon

thelancet.com Favicon

healio.com Favicon

internationaljournalofcardiology.com

Articles

Stopping aspirin 1 month after drug-eluting stent implantation feasible for patients with ACS

Oct 25, 2023 | healio.com | Regina Schaffer |Katie Kalvaitis |B. Hadley Wilson |Myeong-Ki Hong

B. Hadley Wilson, MD, FACCWe have had several studies — TWILIGHT and others — demonstrating that 3 months of DAPT before a switch to ticagrelor monotherapy is effective. In T-PASS, the researchers are peeling back the envelope more, showing that even 1 month of DAPT or less is sufficient after following these patients for 1 year with this short aspirin protocol — the average was 16 days — and continuing ticagrelor for 1 year.
ESC 23: OCEAN(a)-DOSE: Olpasiran in Patients with Atherosclerotic CVD and Elevated LP(a)

Aug 26, 2023 | ecrjournal.com | Gurleen Kaur |Michelle L. O'Donoghue |Myeong-Ki Hong |Mirvat Alasnag

ESC 23 — Dr Michelle O'Donoghue (Brigham and Women's Hospital, US) outlines a trial update from OCEAN(a)-Dose (NCT05581303) in this succinct interview. OCEAN(a)-DOSE (Amgen) was a dose-finding study aiming to evaluate a siRNA, olpasiran, and its effect on risk for coronary heart disease death, myocardial infarction or urgent coronary revascularization when administered subcutaneously as compared to placebo in patients with atherosclerotic cardiovascular disease and elevated Lipoprotein(a).
ESC 23: LODESTAR: Rosuvastatin Vs Atorvastatin Treatment For CAD Patients

Aug 25, 2023 | ecrjournal.com | Myeong-Ki Hong

ESC 23 — Dr Myeong-Ki Hong (Yonsei University College of Medicine, KR) outlines the late-breaking results from the LODESTAR trial (NCT02579499). LODESTAR (Yonsei University) was a randomized, open-label multicenter trial that aimed to compare the clinical efficacy and safety of atorvastatin vs rosuvastatin for the secondary prevention of coronary artery disease.
Tailored treat-to-target strategy feasible vs. high-intensity regimen for CAD

Mar 20, 2023 | healio.com | Regina Schaffer |Richard Smith |Myeong-Ki Hong

Source/Disclosures Source: Hong MK, et al. Featured Clinical Research III. Presented at: American College of Cardiology Scientific Session; March 4-6, 2023; New Orleans (hybrid meeting). Disclosures: Chong Kun Dang Pharmaceutical and Samjin Pharmaceutical funded this study. Hong reports receiving grants from Chong Kun Dang Pharmaceutical and Samjin Pharmaceutical and speaker fees from Edwards Lifesciences, Medtronic and Viatris Korea.